Pharmafile Logo

On GLOBE Final Rule

October 9, 2026 | GLOBE, HEOR, Market Access, Pricing, mfn 

The publication of the GLOBE Final Rule provides important clarity on the administration’s approach to MFN pricing and what it could mean for pharmaceutical pricing, reimbursement, and access strategy globally. Tim Wright tells us more.

promo for Tim's discussion of GLOBE Final Rule

 

To help unpack the implications, EVP, Access & Pricing Tim Wright recently sat down with The Evidence Base to discuss what the rule tells us, how it relates to GENEROUS and GUARD, and the potential consequences for manufacturers, payers, and health systems.

Watch Tim’s GLOBE Final Rule interview

For additional context, his most recent contributions to the MFN discussion include:

If you would like to discuss the implications of the GLOBE Final Rule or broader MFN developments, we’d be happy to arrange a conversation with Tim Wright.

This content was provided by Genesis Research Group

Company Details

 Latest Content from  Genesis Research Group 

On GLOBE Final Rule

The publication of the GLOBE Final Rule provides important clarity on the administration’s approach to MFN pricing and what it could mean for pharmaceutical pricing, reimbursement, and access strategy globally….

Join Genesis Research Group’s October webinar: ‘From scoping to systematic: Choosing the right literature review for your evidence needs’.

On Tuesday, 6 October 2026, Genesis Research Group’s evidence synthesis, HEOR, and evidence planning teams will be presenting an expert webinar on the topic of selecting the right literature review.

Genesis Research Group Appoints Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR

Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence…

Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026

Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it…

MFN Pricing Is Moving Fast – Here’s What Matters

With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it’s a lot to digest. In a new…

ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment

In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on…

Tim Wright Updates ISPOR Europe MFN Pricing Presentation in New Interview

At ISPOR Europe in Glasgow, there were literal queues around the block for Tim Wright’s HEOR Theater presentation ‘MFN Pricing: More Fun to Navigate – A European Roadmap to Success,’ with potentially…

Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212

Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10…

ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs

On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation…

Dave W. Miller interviewed by Paige McGarry on the unique challenges faced by biotech companies

HealthEconomics.com interviews David W. Miller, CEO of Genesis Research Group, to discuss the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.